Keck School Faculty

Etan Orgel

Etan Orgel

Associate Professor of Clinical Pediatrics
CHL 4650 W Sunset Blvd, Off Campus Los Angeles

Assessment of provider perspectives on otoprotection research for children and adolescents: A Children's Oncology Group Cancer Control and Supportive Care Committee survey Pediatr Blood Cancer. 2020 Sep 04; e28647. . View in PubMed

Integrin a6 mediates the drug resistance of acute lymphoblastic B-cell leukemia Blood. 2020 Jul 09; 136(2):210-223. . View in PubMed

Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study Leukemia. 2020 Jul; 34(7):1741-1750. . View in PubMed

Pre-existing or Therapy-induced Mutations in Relapsed Acute Lymphoblastic Leukemia? Blood. 2020 Jun 30.. View in PubMed

Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study Lancet Haematol. 2020 Mar; 7(3):e238-e246. . View in PubMed

Levocarnitine does not impair chemotherapy cytotoxicity against acute lymphoblastic leukemia Leuk Lymphoma. 2020 02; 61(2):420-428. . View in PubMed

Association between Vitamin D and Risk for Early and Late Post-Transplant Complications Biol Blood Marrow Transplant. 2020 02; 26(2):343-350. . View in PubMed

Improving the Timeliness of Chemotherapy Administration in the Bone Marrow Transplant Unit Biol Blood Marrow Transplant. 2020 01; 26(1):150-156. . View in PubMed

Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force Cancer. 2020 02 01; 126(3):593-601. . View in PubMed

Myosteatosis in adolescents and young adults treated for acute lymphoblastic leukemia Leuk Lymphoma. 2019 12; 60(13):3146-3153. . View in PubMed

Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium Lancet Oncol. 2019 01; 20(1):e29-e41. . View in PubMed

Mechanisms by Which Obesity Impacts Survival from Acute Lymphoblastic Leukemia J Natl Cancer Inst Monogr. 2019 09 01; 2019(54):152-156. . View in PubMed

Adipocyte metabolism of the chemotherapy daunorubicin Oncoscience. 2018 May; 5(5-6):146-147. . View in PubMed

Association of clinical trial enrollment and survival using contemporary therapy for pediatric acute lymphoblastic leukemia Pediatr Blood Cancer. 2018 Feb; 65(2). . View in PubMed

The genetic basis and cell of origin of mixed phenotype acute leukaemia Nature. 2018 10; 562(7727):373-379. . View in PubMed

Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis Leukemia. 2018 07; 32(7):1515-1528. . View in PubMed

Obesity and risk for venous thromboembolism from contemporary therapy for pediatric acute lymphoblastic leukemia Thromb Res. 2018 05; 165:44-50. . View in PubMed

Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens Pediatr Blood Cancer. 2018 03; 65(3). . View in PubMed

Limitations of body mass index to assess body composition due to sarcopenic obesity during leukemia therapy Leuk Lymphoma. 2018 01; 59(1):138-145. . View in PubMed

A randomized controlled trial testing an adherence-optimized Vitamin D regimen to mitigate bone change in adolescents being treated for acute lymphoblastic leukemia Leuk Lymphoma. 2017 Oct; 58(10):2370-2378. . View in PubMed

TACL'ing supportive care needs in pediatric early phase clinical trials for acute leukemia: A report from the therapeutic advances in childhood leukemia & lymphoma (TACL) consortium supportive care committee Pediatr Hematol Oncol. 2017 Sep - Oct; 34(6-7):409-417. . View in PubMed

Adipocytes Sequester and Metabolize the Chemotherapeutic Daunorubicin Mol Cancer Res. 2017 12; 15(12):1704-1713. . View in PubMed

Clinical Significance of Isolated Myeloperoxidase Expression in Pediatric B-Lymphoblastic Leukemia Am J Clin Pathol. 2017 04 01; 147(4):374-381. . View in PubMed

Early injury to cortical and cancellous bone from induction chemotherapy for adolescents and young adults treated for acute lymphoblastic leukemia Bone. 2016 Apr; 85:131-7. . View in PubMed

Association of body mass index and survival in pediatric leukemia: a meta-analysis Am J Clin Nutr. 2016 Mar; 103(3):808-17. . View in PubMed

Effect of Sensorineural Hearing Loss on Neurocognitive Functioning in Pediatric Brain Tumor Survivors Pediatr Blood Cancer. 2016 Mar; 63(3):527-34. . View in PubMed

Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia Pediatr Blood Cancer. 2016 11; 63(11):1943-8. . View in PubMed

Clinical and microbiologic outcomes of quinolone prophylaxis in children with acute myeloid leukemia Pediatr Infect Dis J. 2015 Apr; 34(4):e78-84. . View in PubMed

Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia Blood. 2014 Dec 18; 124(26):3932-8. . View in PubMed

Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: A report from the Children's Oncology Group J Clin Oncol. 2014 May 01; 32(13):1331-7. . View in PubMed

Infectious morbidity by catheter type in neutropenic children with cancer Pediatr Infect Dis J. 2014 Mar; 33(3):263-6. . View in PubMed

Efficacy and tolerability of intravenous pentamidine isethionate for Pneumocystis jiroveci prophylaxis in a pediatric oncology population Pediatr Infect Dis J. 2014 Mar; 33(3):319-21. . View in PubMed

Why Healthcare Providers Should Focus on the Fertility of AYA Cancer Survivors: It's Not Too Late! Front Oncol 2013 Oct 07; 3:248. . View in PubMed

Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: a North American perspective Pediatr Blood Cancer. 2013 Sep; 60(9):1528-33. . View in PubMed

The links between insulin resistance, diabetes, and cancer Curr Diab Rep. 2013 Apr; 13(2):213-22. . View in PubMed

Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach Pediatr Blood Cancer. 2012 Jun; 58(6):953-8. . View in PubMed

A failing medical educational model: a self-assessment by physicians at all levels of training of ability and comfort to deliver bad news J Palliat Med. 2010 Jun; 13(6):677-83. . View in PubMed

Dr. Orgel is currently an attending physician on the Medical Supportive Care/Survivorship and Supportive Care Program and the Leukemia and Lymphoma Team within the Division of pediatric Hematology, Oncology, and Blood & Marrow Transplantation at the Children's Hospital Los Angeles (Los Angeles, CA). Dr. Orgel's clinical specialty focuses on higher risk and rare malignant hematology, and specifically, the rare phenomenon of Mixed-Phenotype Acute Leukemia (MPAL). He possesses an academic appointment as an Assistant Professor of Clinical Pediatrics in the Keck School of Medicine of the University of Southern California (USC) following strong training in general pediatrics from Children's National Medical Center (Washington, DC) and a pediatric hematology/oncology fellowship at CHLA. This was complemented with didactic clinical trial training via completing a Masters of Science in Clinical and Biomedical Investigations from the Department of Preventive Medicine at USC.

Dr. Orgel's primary research interest lies in the field of medical supportive care or cancer control (reducing acute and late treatment-related toxicities). His specific focus utilizes a translational research approach to target specific toxic effects to widen therapeutic windows for common chemotherapies and/or improve the quality of life of children with cancer. Currently, Dr. Orgel's active research encompasses studying new agents and novel strategies to reduce hearing loss from chemotherapy (cisplatin), to target obesity in pediatric ALL to improve survival, quality of life, and bone health, and to evaluate resistance to asparaginase (a highly-effective chemotherapy agent) in children with relapsed ALL.
Powered by SC CTSI
Go to Top